Kontafarma China Holdings Valuation
Is 1312 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1312 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1312 (HK$0.03) is trading below our estimate of fair value (HK$0.3)
Significantly Below Fair Value: 1312 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1312?
Key metric: As 1312 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 1312's PS Ratio? | |
|---|---|
| PS Ratio | 0.2x |
| Sales | HK$836.92m |
| Market Cap | HK$173.25m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.4x |
| Enterprise Value/EBITDA | 28.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 1312's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.9x | ||
897 Wai Yuen Tong Medicine Holdings | 0.3x | n/a | HK$236.3m |
1643 Modern Chinese Medicine Group | 1.1x | n/a | HK$249.0m |
858 Extrawell Pharmaceutical Holdings | 2.2x | n/a | HK$129.1m |
8329 Shenzhen Neptunus Interlong Bio-technique | 0.2x | n/a | HK$233.2m |
1312 Kontafarma China Holdings | 0.2x | n/a | HK$173.2m |
Price-To-Sales vs Peers: 1312 is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (0.9x).
Price to Sales Ratio vs Industry
How does 1312's PS Ratio compare vs other companies in the HK Pharmaceuticals Industry?
| 3 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 1.4x | 8.2% | |
1312 Kontafarma China Holdings | 0.2x | n/a | US$22.26m |
3320 China Resources Pharmaceutical Group | 0.1x | 8.0% | US$4.18b |
8329 Shenzhen Neptunus Interlong Bio-technique | 0.2x | n/a | US$29.96m |
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 1.4x | 10.8% | |
1312 Kontafarma China Holdings | 0.2x | n/a | US$22.26m |
Price-To-Sales vs Industry: 1312 is good value based on its Price-To-Sales Ratio (0.2x) compared to the Hong Kong Pharmaceuticals industry average (1.4x).
Price to Sales Ratio vs Fair Ratio
What is 1312's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 1312's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Consun Pharmaceutical Group
HK$6.8b
Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.
1681
HK$8.22
7D
-2.1%
1Y
74.9%
Innovent Biologics
HK$60.6b
A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China.
1801
HK$37.00
7D
-0.5%
1Y
-15.4%
China Shineway Pharmaceutical Group
HK$6.1b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.13
7D
-3.3%
1Y
n/a